--- title: "Bispecific T-Cell" description: "Our curated resources are designed to support the safe, effective implementation of BTCE therapies across a range of clinical settings." canonical: "/bispecific-t-cell" published: 2026-09-30 --- # Bispecific T-Cell ## Hero IMMUNOTHERAPY HUB · BTCE RESOURCES Bispecific T-Cell Engagers, Decoded for Every Care Setting Curated, practice-ready resources supporting the safe, effective implementation ofbispecific T-cell engager therapies (BTCE) therapies — from foundational overviews to agent-specific insights and downloadable SOPs. 3 10 20+ 5 Core Sections Agent Profiles Example SOPs CE Webinars ## Section Nav Recommended Reading Additional Learning Example SOPs & Documents CE Webinars Overview of BTCEs Agent-Specific Resources ## Mission Intro OUR PURPOSE Empowering Teams to Implement Bispecific T-Cell Engager Therapies T-Cell Tumor Cell BTCE Explore practical resources designed to support the safe and effective implementation ofbispecific T-cell engager (BTCE or BiTE) therapies across care settings. Build foundational knowledge, explore agent-specific guidance, and learn from real-world SOPs developed by oncology practices. Simplified mechanism: Abispecific T-cell engagerbridges a T cell and a tumor cell to help drive a targeted immune response. ## Three Pillars WHERE TO START Explore by Resource Type Our resources are divided into three main sections — start wherever fits your team’s current needs. 01 02 03 Overview of BTCEs Agent-Specific Resources Example SOPs and Documents Essential knowledge on BTCEs — key insights and practical guidance for effective clinical implementation. Our “Up Close” series dives deeper into individual agents — dosing, REMS, and administration details. De-identified, real-world protocols and procedures shared by NCODA member practices of every size. [Browse Overview →](widget_Mzur01doR) [Browse Agent Profiles →](widget_8eYVy2usV) [Browse SOPs →](widget_TEtGE5EkF) ## Overview of BTCEs **Anchor: Overview of BTCEs** 01 · FOUNDATIONS Overview of BTCEs Essential knowledge on BTCEs — key insights and practical guidance for effective clinical implementation. Comparison of Bispecific T-Cell Engagers (BTCEs) Engaging with Bispecific T-Cell Engagers A quick-take guide to the essential details of bispecific T-cell engagers. How these agents function, their dosing schedules, notable side effects, and REMS requirements for certain agents. [VIEW RESOURCE →](https://ncoda.org/resource/bispecific-antibody-therapy-resource-guide/) [VIEW RESOURCE →](https://ncoda.org/resource/engaging-with-bispecific-t-cell-engagers/) Clearing Up Confusion Around Bispecific T-Cell Engagers Putting Bispecific T-Cell Engagers into Action A practical guide for operationalizing BTCEs in your practice. Clarifying terminology and highlighting the differences between observation periods and supportive care. [VIEW RESOURCE →](https://ncoda.org/resource/clearing-up-confusion-around-bispecific-antibodies/) [VIEW RESOURCE →](https://ncoda.org/resource/putting-bispecific-t-cell-engagers-into-action/) ## Agent-Specific Resources **Anchor: Agent-Specific Resources** 02 · UP CLOSE SERIES Agent-Specific Resources Dive deeper with focused, agent-level insight — dosing, REMS considerations, and administration details for each BTCE. Epcoritamab-bysp Glofitamab-gxbm Linvoseltamab-gcpt Blinatumomab Elranatamab-bcmm EPKINLY® COLUMVI™ LYNOZYFIC™ BLINCYTO® ELREXFIO™ [View Resource →](https://ncoda.org/resource/up-close-with-epcoritamab/) [View Resource →](https://ncoda.org/resource/up-close-with-blinatumomab/) [View Resource →](https://ncoda.org/resource/up-close-with-elranatamab/) [View Resource →](https://ncoda.org/resource/up-close-with-linvoseltamab/) [View Resource →](https://ncoda.org/resource/up-close-with-glofitamab/) Mosunetuzumab-axgb Talquetamab-tgvs Tarlatamab-dlle Tebentafusp-tebn Teclistamab-cqyv LUNSUMIO™ TALVEY® IMDELLTRA™ KIMMTRAK® TECVAYLI® [View Resource →](https://ncoda.org/resource/up-close-with-mosunetuzumab/) [View Resource →](https://ncoda.org/resource/up-close-with-talquetamab/) [View Resource →](https://ncoda.org/resource/up-close-with-tarlatamab/) [View Resource →](https://ncoda.org/resource/up-close-with-tebentafusp/) [View Resource →](https://ncoda.org/resource/up-close-with-teclistamab/) ## Example SOPs and Documents **Anchor: Example SOPs & Documents** 03 · REAL-WORLD PRACTICE Example SOPs and Documents Sample protocols and procedures shared by NCODA member practices - de-identified, with details on clinic size to help you find the right fit. Education AE Management Inpatient Use of BTCE • Staff Education for Using Bispecific T-Cell Engagers • Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management • Inpatient Use of Bispecific T-Cell Engagers Mid-sized, Community Large Academic Center Mid-sized, Rural Community [View Resource →](https://ncoda.org/resource/staff-education-for-using-bispecific-t-cell-engagers/) [View Resource →](https://ncoda.org/resource/inpatient-use-of-bispecific-t-cell-engagers/) [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-associated-cytokine-release-syndrome-crs-management-mid-sized/) • Patient Education (Coming Soon) Mid-sized, Partial Integrated, Community • Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management Coming Soon → Large Community [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-associated-cytokine-release-syndrome-crs-management-large/) • Bispecific T-Cell Engager Associated Cytokine Release Syndrome (CRS) Management Ordering & Billing On-Call & Triaging Practices • Bispecific T-Cell Engager Ordering and REMS Compliance • On-Call Symptom Interventions for Patients Receiving Bispecific T-Cell Engagers Large Academic Center Mid-sized, Community Satellites Coming Soon → Mid-sized, Community [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-ordering-and-rems-compliance-mid-sized/) • Bispecific T-Cell Engager Neurotoxicity Management [View Resource →](https://ncoda.org/resource/on-call-symptom-interventions-for-patients-receiving-bispecific-t-cell-engagers-mid-sized/) • Bispecific T-Cell Engager Billing Procedure Mid-sized, Rural Community • Telephone Triage of Patients Undergoing Bispecific T-Cell Engager Therapy Mid-sized, Community [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-neurotoxicity-management-mid-sized/) [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-billing-procedure-mid-sized/) • Bispecific T-Cell Engager Neurotoxicity Management Mid-sized, Community [View Resource →](https://ncoda.org/resource/telephone-triage-of-patients-undergoing-bispecific-t-cell-engager-therapy-mid-sized/) Large Community • On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-neurotoxicity-management-large/) Transitioning Patients • Bispecific T-Cell Engager Neurotoxicity Management Mid-sized, Community • Transitioning Patients Between Care Settings [View Resource →](https://ncoda.org/resource/on-call-responsibilities-for-nurses-managing-bispecific-t-cell-engagers-mid-sized/) Large Academic Center Mid-sized, Partial Integrated, Community [View Resource →](https://ncoda.org/resource/bispecific-t-cell-engager-neurotoxicity-management-academic/) [View Resource →](https://ncoda.org/resource/transitioning-patients-on-bispecific-t-cell-engagers-between-care-settings-mid-sized/) ## CE Webinars **Anchor: CE Webinars** ON-DEMAND LEARNING CE Webinars Earn continuing education credit while learning directly from practicing clinicians and pharmacists. Adverse Effects Associated with Bispecific T-Cell Engagers Nicholas Bitz, PharmD, MBA · C. Brooke Adams, PharmD, BCOP **CE Registration Link** 1 CE CREDIT Advanced Practice Provider and Pharmacy Perspectives on BTCEs Nicholas Bouchard, PharmD · Denise Lougee, MS-PAS, RPA-C **CE Registration Link** 1 CE CREDIT Education and Training for Staff and Patients Regarding BTCEs Eden Biltibo, MD, MS · Kristen Kingma, DNP, RN, OCN **CE Registration Link** 1 CE CREDIT Patient’s EHR and BTCE Therapy: Documentation and Billing Stephanie S. Waddoups, RN, BSN **CE Registration Link** 1 CE CREDIT Outpatient Step-Up Dosing of Bispecific T-Cell Engagers Tara Graff, DO, MS · Kelly Brunk, PharmD, BCOP ON DEMAND Explore the Full CE Library [View All Webinars →](https://ncoda.org/continuing-education/) ## Additional Resources **Additional Learning Anchor** ADDITIONAL LEARNING Related Resources ### Content Name **Read More →** Type Showing 0-0 of 0 Assets ## Reading and Acknowledgements **Anchor: Recommended Reading** CITATIONS Recommended Reading - Atembina L, Boehmer L, Terrell K, et al. Multidisciplinary provider insights to promote adoption of bispecific antibodies to treat cancer in the community. Blood. 2021;138(Supplement 1):4033. doi:10.1182/blood-2021-153794. - Carlisle JW, O'Reilly K, Ji XA, et al. Real-world implementation of tarlatamab-dlle therapy for patients with extensive-stage small cell lung cancer and other high-grade neuroendocrine neoplasms. JCO Oncol Pract. Published online July 8, 2026. doi:10.1200/OP-26-00074. - Cheema PK, Perdrizet KA, Sangha RS, et al. Early experience with tarlatamab (T-cell engagers) for extensive-stage small cell lung cancer (ES-SCLC) in Canada: lessons learned and implementation strategies. Curr Oncol.2026;33(2):84. Published January 31, 2026. doi:10.3390/curroncol33020084. - Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143(16):1565-1575. doi:10.1182/blood.2023022432. - Garfall AL, Banerjee R, Frenzel L, et al. A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Front Oncol. 2025;15:1630146. Published July 30, 2025. doi:10.3389/fonc.2025.1630146. - Gonugunta AS, Haider A, Mohlere V, Aljurf M, Hashmi S, Abid MB. Bispecific antibodies in hematologic malignancies in the outpatient and community settings. Adv Hematol. 2026;2026:4529571. Published May 7, 2026. doi:10.1155/ah/4529571. - Lee DW, Santomasso BD, Meyer FL, et al. ASTCT consensus grading for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758. - Lund T, Khandanpour C, Anguille S, et al. European expert panel consensus on outpatient administration of teclistamab and talquetamab in patients with multiple myeloma: feasibility, key considerations, and future directions. Eur J Haematol. 2025;115(4):358-366. doi:10.1111/ejh.14444. - Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol. Published online September 11, 2024. doi:10.6004/jadpro.2024.15.8.15. - Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020;8(2):e001511. doi:10.1136/jitc-2020-001511. - Oranges K, Duffy KA, McDonough S, et al. Real-world pediatric blinatumomab administration: access to outpatient care delivery and impact of a hospital-dispensed model. Pediatr Blood Cancer.2026;73(7):e70314. doi:10.1002/1545-5017.70314. - Pelland AA, Dumas M, Lemieux-Blanchard É, et al. Perspectives on outpatient delivery of bispecific T-cell engager therapies for multiple myeloma. Curr Oncol. 2025;32(4):238. Published April 18, 2025. doi:10.3390/curroncol32040238. - Puttkammer JR, Barreto JN, Jensen CJ, et al. Outpatient management of bispecific related toxicities: an observational study of safety outcomes and resource utilization. JCO Oncol Pract. 2026;22(1):83-90. doi:10.1200/OP-24-00930. - Rahbari KJ, Mijares RDT, Kennedy K, et al. Outpatient administration of bispecific antibody therapy for hematologic malignancies: a practical guide. JCO Oncol Pract. Published online December 4, 2025. doi:10.1200/OP-25-00652. - Resnick Y, Boland P, Winters JP. Implementation of a model program at an independent community oncology practice for the outpatient administration of B-cell maturation antigen-directed bispecific antibody step-up doses. JCO Oncol Pract. Published online April 23, 2026. doi:10.1200/OP-25-00585. - Scott SA, Roberts DL, Gupta VA, et al. Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting oral abstract. Clin Lymphoma Myeloma Leuk. 2025;25(9):656-660. doi:10.1016/j.clml.2025.04.002. - Song Y, Zhou X, Wang L. Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care. Front Oncol. 2026;16:1859755. Published June 9, 2026. doi:10.3389/fonc.2026.1859755. WITH GRATITUDE Acknowledgements Our heartfelt gratitude to all who contributed key insights to the development of these resources, including: Allison Mendoza, PharmD Bob Phelan, RPh Bradley Yelvington, PharmD, BCOP C. Brooke Adams, PharmD, BCOP Corey Jordan, PharmD Emilie Aschenbrenner, PharmD, BCOP Jane Osterson, RN Justin Konkol, PharmD, BCPS Denise Lougee, MSPAS, RPA-C Eden Biltibo, MD, MSCI Kristin Kingma, DNP, RN, AGCNS-BC, OCN Joyce Wong, MD Kevin Krueger, PharmD, MBA Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, FHOPA Maddie Koppin, PharmD Melinda Rhoades, PharmD, BCOP Mike Seppelfrick, PharmD Man-Yee Merl, PharmD, BCOP Nicholas Bitz, PharmD, MBA, MSPGx Nick Bouchard, PharmD Sam Abdelghany, PharmD, MHA, BCOP Stephanie Waddoups, RN, BSN Stephen Clark, PharmD, BCOP Tara Graff, DO, MS Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ## Membership CTA Ready to Bring BTCE Best Practices to Your Team? Join NCODA’s community of 17,000+ oncology professionals for full access to the Immunotherapy Hub and our entire clinical resource library. **Join Now** **Explore Resource Library**